U.S. Markets closed
  • S&P Futures

    4,030.50
    -5.25 (-0.13%)
     
  • Dow Futures

    32,696.00
    -78.00 (-0.24%)
     
  • Nasdaq Futures

    12,908.75
    +41.50 (+0.32%)
     
  • Russell 2000 Futures

    1,779.90
    -13.40 (-0.75%)
     
  • Crude Oil

    70.41
    +0.74 (+1.06%)
     
  • Gold

    1,951.80
    +10.70 (+0.55%)
     
  • Silver

    22.81
    +0.39 (+1.72%)
     
  • EUR/USD

    1.0794
    +0.0022 (+0.2051%)
     
  • 10-Yr Bond

    3.5560
    -0.0500 (-1.39%)
     
  • Vix

    21.10
    -0.28 (-1.31%)
     
  • GBP/USD

    1.2253
    +0.0034 (+0.2806%)
     
  • USD/JPY

    132.5800
    +0.1200 (+0.0906%)
     
  • BTC-USD

    27,315.51
    -857.98 (-3.05%)
     
  • CMC Crypto 200

    615.59
    -0.36 (-0.06%)
     
  • FTSE 100

    7,566.84
    +30.62 (+0.41%)
     
  • Nikkei 225

    27,466.61
    +520.94 (+1.93%)
     

GeoVax to Present at the 2023 BIO CEO & Investor Conference

GeoVax, Inc.
GeoVax, Inc.

ATLANTA, GA, Jan. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that its Chairman and CEO, David Dodd, will present at the 2023 BIO CEO & Investor Conference taking place in-person in New York City at the New York Marriott Marquis and virtually on February 6-9, 2023.

BIO CEO & Investor Conference

Date: Tuesday, February 7, 2023

Time: 3:45 PM EST

An on-demand video presentation will also be available for conference participants during the event.

GeoVax will also conduct one-on-one meetings during the conference. For more information or to schedule a meeting, please visit the conference page here or email Investor Relations at govx@cg.capital.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Contact:
Rich Cockrell
CG Capital
404-736-3838
govx@cg.capital